Webinar
Webinar panelists:
The future of medicine lies in advanced cell engineering, where precision, efficiency, and scalability are key to developing transformative therapies. MaxCyte® is leading the way with its cutting-edge Flow Electroporation® technology and SeQure Dx™ gene editing risk assessment services, empowering researchers to develop safer, more effective treatments. To maximize efficiency, ensure compliance, and streamline research workflows, MaxCyte integrates SciNote’s electronic lab notebook (ELN) into its processes.
In this webinar, Dr. Jim Brady and Dr. Ashley Strickland-Dietz from MaxCyte will explore how non-viral cell engineering is propelling next-generation medicines forward. They will also discuss how SciNote plays a critical role in supporting their research documentation and collaboration. Additionally, Kelli Mangold, Customer Success Manager at SciNote, will provide insights into best practices for successfully integrating SciNote into scientific workflows, helping teams optimize research efficiency and regulatory preparedness.
Time/date: Thursday April 10th at 9AM EDT/; 6AM PDT; 3PM CET
Duration: 1 hour
Can’t attend live? Register anyway, and we’ll send you the recording!
Dr. Jim Brady is Senior Vice President of Technical Applications and Customer Support at MaxCyte, Inc, where he manages the company’s internal scientific research activities. Jim is an experienced biotechnology industry professional with expertise in gene and cellular therapy, biologics, and drug discovery. Previously, he was a Senior Scientist at Genetic Therapy, a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments, and a Group Leader at MetaMorphix, Inc, managing the company’s transgenic and genetic research programs.
Dr. Ashley Strickland-Dietz is an Immunology Scientist at MaxCyte, where she develops cell engineering workflows for various immune cells including monocytes, macrophages and T cells. Ashley graduated from the University of Maryland, Baltimore County with a Bachelor of Science in Biochemistry and Molecular Biology and went on to obtain a Master of Science in Applied Molecular Biology. Afterward she worked as a researcher at the Johns Hopkins University School of Medicine where she investigated lung macrophage immunobiology during allergic asthma. She continued to study immunology at the University of Maryland, College Park where she was awarded a Doctorate Degree in Comparative Biomedical Sciences for her work examining T cell regulation and macrophage dysfunction in the lungs and brain during infection with fungal pathogens.
Kelli Mangold is a Customer Success Manager at SciNote, dedicated to helping researchers streamline their workflows and maximize the value of digital lab solutions. With a background in education and agricultural sciences, she brings a unique ability to understand diverse needs and deliver tailored solutions. Her empathetic approach and commitment to sustainable values make her a trusted advisor in ensuring scientists get the most out of their digital lab solutions.
MaxCyte® is a leading cell-engineering company advancing the discovery, development, and commercialization of next-generation cell therapies. The company’s Flow Electroporation® technology and SeQure Dx™ gene editing risk assessment services provide precise, efficient, and scalable solutions for cell engineering. Supported by comprehensive scientific, technical, and regulatory expertise, MaxCyte’s ExPERT™ platform enables researchers to engineer a wide range of cell types and payloads, accelerating the development of safe and effective treatments. With more than 25 years of experience in cell engineering, MaxCyte continues to shape the future of medicine. Learn more at www.maxcyte.com. Let’s Build Better Cells Together.™
Discover what SciNote can do for you. Get a proof of concept with our premium support and custom-tailored experience.
Receive SciNote ELN news, webinars and articles.